|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: A randomized controlled trial显示文摘 | Kapil Sharma Sanjay Pant Sriprakash Misra Manisha Dwivedi Alok Misra Sushil Narang Reshu Tewari Ajeet Bhadoria | 2014 | Saudi Journal of Gastroenterology2014，，4： | 2 |
| 2 | Recent developments in dynamic contrast-enhanced ultrasound imaging of tumor angiogenesis显示文摘 | Reshu Saini Kenneth Hoyt | 2014 | Imaging in Medicine2014，，： | 1 |
| 3 | Effct of automobile exhausts on some biochemical characteristic of rpad side triticumaestivuml 显示文摘 | Reshu | 2005 | Advances in Plant Sciences2005，18，2： | 1 |
| 4 | Radiation-inducible silencing of uPA and uPAR in vitro and in vivo inmeningioma显示文摘 | Venkateswara Rao Gogineni Arun Kumar Nalla Reshu Gupta Bharathi Gorantla Meena Gujrati Dzung Dinh Jasti Rao | 2010 | International Journal of Oncology2010，，4： | 1 |
| 5 | Association of benign prostatic hyperplasia (BPH) with the metabolic syndrome (MS) and its components‘a growing dilemma’ 显示文摘 | RESHU T PAWNI P NATU SM | 2011 | J Mens Health2011，8，1： | 1 |
| 6 | Nonalcoholic Fatty Liver Disease(NAFLD)Name Change:Requiem or Reveille?显示文摘Nonalcoholic fatty liver disease(NAFLD)affects about a quarter of the world’s population and poses a major health and economic burden globally.Recently,there have been hasty attempts to rename NAFLD to metabolic-associated fatty liver disease(MAFLD)despite the fact that there is no scientific rationale for this.Quest for a“positive criterion”to diagnose the disease and destigmatizing the disease have been the main reasons put forth for the name change.A close scrutiny of the pathogenesis of NAFLD would make it clear that NAFLD is a heterogeneous disorder,involving different pathogenic mechanisms of which metabolic dysfunction-driven hepatic steatosis is only one.Replacing NAFLD with MAFLD would neither enhance the legitimacy of clinical practice and clinical trials,nor improve clinical care or move NAFLD research forward.Rather than changing the nomenclature without a strong scientific backing to support such a change,efforts should be directed at understanding NAFLD pathogenesis across diverse populations and ethnicities which could potentially help develop newer therapeutic options. | Shivaram P.Singh Prajna Anirvan Reshu Khandelwal Sanjaya K.Satapathy | 2021 | Journal of Clinical and Translational Hepatology2021，9，6： | 1 |
| 7 | Performance evaluation of NeuMoDx 96 system for hepatitis B and C viral load显示文摘BACKGROUND Hepatitis B virus(HBV)and hepatitis C virus(HCV)viral load(VL)estimation is essential for the management of both HBV and HCV infections.Due to a longer turnaround time for VL estimation,many patients drop out from the cascade of care.To achieve the global goals of reducing morbidity and mortality due to HBV/HCV and moving towards their elimination by 2030,molecular diagnostic platforms with faster and random(i.e.single sample)access are needed.AIM To evaluate the performance of the recently launched NeuMoDx 96 random access system with the conventional COBAS^(■)AmpliPrep/COBAS TaqMan system for HBV and HCV VL estimation.METHODS Archived once-thawed plasma samples were retrieved and tested on both platforms.Correlation between the assays was determined by linear regression and Bland-Altman analysis.The study included samples from 186 patients,99 for HBV of which 49 were true infected HBV cases(hepatitis B surface antigen,antihepatitis B core antibody,and HBV DNA-positive)and 87 for HCV assay in which 39 were true positives for HCV infection(anti-HCV and HCV RNA-positive).RESULTS The median VL detected by NeuMoDx for HBV was 2.9(interquartile range[IQR]:2.0-4.3)log_(10)IU/mL and by COBAS it was 3.70(IQR:2.28-4.56)log_(10)IU/mL,with excellent correlation(R2=0.98).In HCV,the median VL detected by NeuMoDx was 4.9(IQR:4.2-5.4)log_(10)IU/mL and by COBAS it was 5.10(IQR:4.07-5.80)log_(10)IU/mL with good correlation(R2=0.96).CONCLUSION The overall concordance between both the systems was 100%for both HBV and HCV VL estimation.Moreover,no genotype-specific bias for HBV/HCV VL quantification was seen in both the systems.Our findings reveal that NeuMoDx HBV and HCV quantitative assays have shown overall good clinical performance and provide faster results with 100%sensitivity and specificity compared to the COBAS AmpliPrep/COBAS TaqMan system. | Gagan Chooramani Jasmine Samal Nitiksha Rani Gaurav Singh Reshu Agarwal Meenu Bajpai Manoj Kumar Manya Prasad Ekta Gupta | 2023 | World Journal of Virology2023，12，4： | 0 |
| 8 | Non-alcoholic fatty liver disease in diabetes:When to refer to the hepatologist?显示文摘Non-alcoholic fatty liver disease(NAFLD)has become one of the most common chronic liver diseases worldwide.A strong relationship exists between NAFLD and diabetes mellitus.There is growing evidence of a mechanistically complex and strong association between the two diseases.Current data also shows that one disease actually leads to worsening of the other and vice versa.Understanding of the various pathophysiological mechanisms involved,natural history and spectrum of these two diseases is essential not only for early diagnosis and management but also for prevention of severe disease forms.Despite the tremendous progress made in recent times in acquiring knowledge about these highly prevalent diseases,the guidelines and recommendations for screening and management of diabetics with NAFLD remain ambiguous.An interdisciplinary approach is required to not only raise awareness of the prevalence of NAFLD in diabetics but also for better patient management.This can help attenuate the development of significant complications,such as cirrhosis,decompensation and hepatocellular carcinoma in these patients,thereby halting NAFLD in its tracks.This review focuses on the pivotal role of primary care physicians and endocrinologists in identification of NAFLD in diabetics in early stages and the role of proactive screening for prompt referral to hepatologist. | Reshu Khandelwal Anuradha S Dassanayake Hari S Conjeevaram Shivaram P Singh | 2021 | World Journal of Diabetes2021，12，9： | 0 |
| 9 | Prolonged existence of SARS-CoV-2 RNAs in the extracellular vesicles of respiratory specimens from patients with negative reverse transcription-polymerase chain reaction显示文摘Background and aim:Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is primarily in the respiratory tract,particularly in patients with underlying comorbidities.This study aimed to investigate the presence of the virus inside the extracellular vesicles(EVs)in patients with and without chronic liver disease(CLD).Methods:Eighty patients with positive SARS-CoV-2,including twenty-four patients with CLD and fiftysix patients without CLD,and five healthy controls with negative SARS-CoV-2 were enrolled.Nasal swab specimens were tested for the detection of SARS-CoV-2 using reverse transcription-polymerase chain reaction(RT-PCR).Patients with coronavirus disease 2019(COVID-19)were followed up on days 7 and 14.Nasal swab,collected in viral transport media(VTM),and plasma samples were investigated at each time point.EVs were isolated from the nasal swabs(collected in VTM)and plasma using differential ultracentrifugation and estimated at each time point.The transmission or replication by the EVs was assessed in Vero E6 cells.Results:In patients with baseline RT-PCR positive,SARS-CoV-2 RNAs inside the EVs were found in 68/80(85%)patients with higher viral load in the nasal swabs than in the EVs(cycle threshold(Ct)value,23.4±5.7 vs.30.3±5.0,P<0.001).On follow-up at day 7,of the 32 patients negative for COVID-19,15(46.9%)had virus persistence in the EVs(Ct value,30.7±2.7),and on day 14,of the 56 patients with negative SARS-CoV-2,16 patients(28.6%)had positive SARS-CoV-2 RNAs in the EVs(Ct value,31.4±3.0).The mean viral load decreased on days 7 and 14 compared to baseline in the nasal swabs(P<0.001)but not in the EVs.Additionally,SARS-CoV-2 RNAs were undetectable in the plasma,but 12.5% of patients were positive in the plasma EVs.Significantly prolonged and high viral load was found in the EVs on day 14 in COVID-19 patients combined with CLD compared with COVID-19 patients(P?0.0004).We found significant higher levels of EV-associated with endothelial cells and hepatocytes in the COVID-19 t CLD group than COVID-19 group(P?0.032 and P?0.002,respectively),suggesting more endothelial cells and hepatocytes cellular injury in liver disease patients with COVID-19.Interestingly,we also found EVs could transmit SARS-CoV-2 RNAs into Vero E6 cells at 24 h post-infection.Conclusions:The identification of SARS-CoV-2 RNAs in the EVs in patients with negative RT-PCR indicates the persistence of infection and likely recurrence of the infection.It is suggestive of another route of transmission as EVs harbor SARS-CoV-2 RNAs.EV-associated RNAs may determine the ongoing inflammation and clinical course of subjects with undetectable SARS-CoV-2 virus and this may have relevance to better management of patients with CLD. | P.Debishree Subudhi Sheetalnath Rooge Chhagan Bihari Swati Thangariyal Sivang Goswami Reshu Agarwal Savneet Kaur Ekta Gupta Sukriti Baweja | 2023 | Liver Research2023，7，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员